Review · e0028

Prostate cancer: to treat or not to treat, a cautionary tale from a doctor-patient

Dr Leslie Jackowski B.Sc.(Hons) MBBS (retired)✉

From Stokes Hill Lookout in the Flinders Ranges, the sun sets behind Bunker’s Range, setting a vast sky of layered cloud alight in pink and crimson above the rolling, rust-red hills below. Photograph by Dylan Toh, FRACP; more of his photography can be found at www.everlookphotography.com.

Correspondence to: Leslie Jackowski — lesliejackowski@gmail.com

Cite as: Jackowski L. Prostate cancer: to treat or not to treat, a cautionary tale from a doctor-patient. South Aust J Med. 2026;1(2):e0028.

DOI: 10.66861/ULPY7964 Open access · CC BY 4.0

Abstract

Background: A definitive diagnosis of prostate cancer can be established with a special type of MRI (multiparametric MRI) followed by core biopsy. An assessment of stage (extent of spread) and grade (aggressiveness of disease) from these investigations assists with clinical decision-making regarding early management.

Objective: This article describes the evidence supporting active surveillance for low-risk prostate cancer and the limitations of diagnostic tools in choosing between active surveillance and surgery (radical prostatectomy) for newly diagnosed prostate cancer. It addresses an important aspect of patient safety and aims to inform physicians and (through them) patients. The article also discusses the potential adverse outcomes of radical prostatectomy and issues relating to biochemical recurrence after surgery. Radiation therapy lies outside the scope of this article.

Discussion: mpMRI / core biopsy can significantly underestimate the stage and grade of prostate cancer, and there is a risk that the disease could be a higher stage and/or grade than is appropriate for active surveillance. A real-life clinical vignette illustrates that prostate cancer initially diagnosed as stage T2 / grade group 1 (low risk) quickly proved (post-surgically) to be stage T3 / grade group 2 (high risk). The former would have been a candidate for active surveillance; the latter would not. When appropriate, prostatectomy should not be avoided because of fear of adverse effects. The definition and clinical relevance of biochemical recurrence continue to be debated.

Editor’s preface

His own cancer looked, on every pre-operative scan and biopsy, like a textbook case for watchful waiting. Surgery told a different story. A retired doctor’s account of how far diagnostic imaging can fall short of the truth — and why fear of surgical side effects is not a reason to choose the safer-looking option.

— The Editors

Key points

  • Diagnostic tools can underestimate both stage (extent of spread) and grade (aggressiveness) of prostate cancer.
  • Definitive stage and grade of disease can be established only by histological analysis following surgery (prostatectomy).
  • Active surveillance is a valid management option for low-risk prostate cancer, supported by long-term outcomes in clinical trials. However, it is not without risk, and a window of opportunity for curative therapy could be missed.
  • Surgery may be lifesaving and should not be avoided through fear of potential adverse events.
  • Multiple definitions have been proposed for biochemical recurrence (BCR) of prostate cancer following definitive therapy such as surgery. An indication for further investigation/therapy should not be based solely on meeting a threshold BCR prostate-specific antigen (PSA) value, but should also reflect the individual’s risk of disease progression.

Aim

This article aims to address an important aspect of patient safety relating to the use of mpMRI and core biopsy for decision-making in the management of newly diagnosed prostate cancer. The article incorporates information from a real-life scenario involving a doctor-patient with prostate cancer, and aims to inform physicians and (through them) patients. Radical prostatectomy as a potentially curative treatment is discussed, as is the concept/clinical relevance of BCR following prostatectomy.

Introduction

A clinical suspicion of prostate cancer is generally based on a patient’s medical history and symptoms along with elevated PSA levels in the blood. If prostate cancer is suspected, mpMRI followed by a core biopsy (for MRI-positive cancer) can establish a diagnosis and help assist decision-making regarding management. It is important to inform patients that both MRI and core biopsy are painless (biopsy is performed under local or general anaesthesia), and that the risk of infection is very low with trans-perineal biopsy as compared with trans-rectal biopsy.

Stage and grade of disease

Stage and grade are two key parameters in deciding whether to actively treat newly diagnosed prostate cancer.

Stage of disease indicates how far the cancer has spread. A simplified summary of the stages of prostate cancer is presented in Table 1.

StageGrade group
T1Cancer is confined to the prostate and is not widespread within the gland.
T2Cancer is confined to the prostate but is larger and more widespread within the gland than T1.
T3Cancer has grown outside the prostate. It may have spread to the seminal vesicles.
T4Metastatic disease. Cancer has spread to other parts of the body such as bone, rectum or bladder.
Table 1. Stages of prostate cancer

T1, T2 and T3 also contain sub-stages. T1, T2 and T3 stage cancers have high survival rates; T4 disease does not (only about 30% of men with T4 disease will be alive after five years).

Grade reflects how aggressive the prostate cancer is, that is, its potential to spread (metastasise). Grade groups are established by histological analysis of samples of prostate tissue (core biopsy or the whole gland after prostatectomy). There are five grade groups, numbered 1 to 5, with 1 being the least aggressive cancer and 5 the most. These grade groups simplify and relate to the more complex Gleason score (see Table 2). Note that a Gleason score of 3 + 4 = 7 is not the same as a Gleason score of 4 + 3 = 7, with the former carrying a lower risk of metastasis than the latter.

Grade groupGleason scoreRisk of metastases
13 + 3 = 6Low
23 + 4 = 7Intermediate (favourable)
34 + 3 = 7Intermediate (unfavourable)
48High
59–10Very high
Table 2. Grades of prostate cancer Risk of metastasis is defined by the grade group of the cancers, but risk calculation may also use other parameters, such as PSA levels, clinical tumour stage (T stage), PSA density and the number of positive biopsy cores.

Active surveillance

Active surveillance does not actively treat prostate cancer but monitors for cancer progression with regular investigations (PSA levels, mpMRI and biopsy). It aims to allow for active treatment with curative intent should the cancer progress. Both the Prostate Cancer Foundation of Australia and the Cancer Council of Australia define criteria for active surveillance as stage T1–T2 disease and grade group 1 (Gleason 3 + 3) and PSA < 10 ng/mL.1,2 About 80% of Australians with low-risk prostate cancer choose active surveillance.2 Selected patients with grade group 2 disease (Gleason 3 + 4) may also be considered for active surveillance.

Active surveillance—the PASS study

The Canary Prostate Active Surveillance Study (PASS) is a prospective cohort study initiated in 2008.3 A cohort of 2155 men (mean age 63 years) with favourable-risk prostate cancer and no prior treatment were selected for active surveillance. Some 90% of patients were diagnosed with grade group 1 cancer and 99% had T1 or T2 disease; 98% had very low, low or favourable intermediate-risk prostate cancer.

Active surveillance involved PSA testing and biopsies at 6–12 months after diagnosis, two years after diagnosis, and then every two years. Other studies, including MRI and biomarker tests, which have come into clinical use since the inception of PASS, were performed at the clinicians’ discretion. Clinic visits occurred every six months until definitive treatment (such as prostatectomy), after which, clinical data (e.g. tests to monitor prostate cancer, treatments and outcomes) were collected annually. Results are shown in Table 3.

Outcome10-year incidence
Grade reclassification43%
Definitive treatment49%
Development of metastatic disease1.4%
Prostate-specific mortality0.1%
All-cause mortality5.1%
Table 3. Results of the PASS study

These results support active surveillance as an effective and safe strategy for men diagnosed with favourable-risk prostate cancer.

Active surveillance versus prostatectomy

Two long-term clinical trials have assessed the efficacy and adverse outcomes of monitoring versus prostatectomy for men with prostate cancer. The monitoring in these trials was PSA-based and did not include regular scheduled mpMRI or regular scheduled surveillance biopsies—tools that are used in modern active surveillance protocols to identify men that will need definitive treatment. In the ProtecT trial, monitoring was termed ‘active monitoring’ and in the PIVOT trial ‘observation’.

The ProtecT trial randomised 1643 men (median age at diagnosis 62 years) with localised prostate cancer to receive active monitoring (N = 545), prostatectomy (N = 553) or radiotherapy (N = 545) between 1999 and 2009.4 Approximately one-third were assessed as having intermediate or high-risk disease by contemporary risk stratification criteria. Follow-up lasted a median of 15 years and was complete for 1810 patients (98%).

The PIVOT trial randomly assigned 731 men (mean age 67 years) with localised prostate cancer to prostatectomy (N = 364) or observation (N = 367) between 1994 and 2002. Follow-up lasted nearly 20 years (median follow-up 12.7 years).5

Results of the ProtecT and PIVOT trials are summarised in Table 4.

OutcomeProtecT trial (15 years of follow-up)PIVOT trial (19.5 years of follow-up)
Death from prostate cancerNo significant differenceNo significant difference
Death from any causeNo significant differenceNo significant difference
Disease progressionSignificantly increased in monitoring groupSignificantly increased in monitoring group
Development of metastatic diseaseSignificantly increased in monitoring groupNot reported**
Initiation of long-term androgen therapySignificantly increased in monitoring groupNot reported
Table 4. Outcomes of the ProtecT and PIVOT trials — Monitoring v. Prostatectomy **At a median follow-up of 10 years in the PIVOT trial, the development of metastatic disease was significantly increased in the observation group compared with prostatectomy.6

A substantial number of men in the active monitoring group of the ProtecT trial received some form of therapy during the trial. Some 30% of these underwent either prostatectomy or radiotherapy within three years, a percentage that increased to 55% at 10 years and 61% at 15 years.

In the PIVOT trial, 75 men (20.4%) in the observation group received some form of definitive therapy, 37 of whom had a prostatectomy.

One of the issues with such long-term follow-up studies is that monitoring protocols in clinical practice change over time as new investigative tools emerge and/or as protocols are reassessed. For example, multiparametric MRI for detecting prostate cancer emerged in the mid-2000s. The monitoring protocols of both the ProtecT and PIVOT trials (launched in 1994 and 1999 respectively) did not fundamentally change during the studies, so their approach to monitoring differs significantly from modern active surveillance protocols. However, despite using less-intensive monitoring protocols than are currently employed in clinical practice, both the ProtecT and PIVOT trials showed no significant difference in prostate-cancer-related mortality or death from any cause between the monitoring and radical prostatectomy groups.

Active surveillance—limitations

Diagnostic mpMRI/core biopsy of an un-excised prostate can establish a diagnosis of prostate cancer, give an indication of the stage and grade of disease, and guide management decision-making. For example, if mpMRI/core biopsy indicate stage T2 / grade group 1 disease, the patient might be offered active surveillance rather than active treatment with surgery or radiotherapy.

However, several studies have found that mpMRI frequently and significantly underestimates size and stage of prostate cancer. This underestimate has been reported in up to 80% of cases.7–9 Perhaps most significantly, mpMRI has low sensitivity (58%) for detecting extracapsular extension (T3 disease) because it cannot detect microscopic cancer spread beyond the capsule. This leads to under-staging of disease with minimal extracapsular extension (i.e. the cancer is staged as T1 or T2, but is actually T3).10 This is a crucial difference, because a man with T1 or T2 disease may be a candidate for active surveillance, but one with T3 disease is not. The clinical vignette that follows illustrates this issue.

Core biopsy underestimates the true grade of disease in about 20% of patients because the biopsy needles occasionally miss an area of higher-grade cancer,7 as is also illustrated below.

A 2014 study found that of 415 patients whose prostate cancer was initially classified as Gleason 3 + 3, just over half (209 patients) were found to have a more aggressive disease when histologically assessed after prostatectomy. Almost one-third (131 patients) had cancers that had spread beyond the prostate gland. The study highlighted the uncertainty associated with selecting men for active surveillance. The authors concluded that in counselling patients for active surveillance, the treating physician should explicitly state the uncertainty in predicting stage/grade of disease at initial diagnosis.11

In summary, initial assessment by mpMRI/core biopsy that a patient is a candidate for active surveillance carries a risk that the cancer could be a higher stage and/or grade than is appropriate for such an approach.

Clinical vignette

A 67-year-old retired doctor with a PSA < 10 ng/mL was assessed as having stage T2 / grade group 1 prostate cancer by mpMRI/core biopsy. PI-RADS score for the mpMRI was 4 (see Appendix 1), tumour size = 9 mm × 5 mm. The patient had a complex medical history, including thyroid cancer (possibly caused by radiation therapy for acne as a teenager), multiple (>20) basal cell carcinomas and two parotid tumours that proved to be benign. Despite meeting the criteria for active surveillance, the treating urologist recommended that he have robotic radical prostatectomy and the patient agreed.

Definitive staging/grading of prostate cancer can be established only by microscopic examination of the whole gland after it has been surgically removed. In this case, disease that had been assessed as stage T2 / grade group 1 by diagnostic mpMRI/core biopsy proved post-surgically to be stage T3 / grade group 2, and hence not a candidate for active surveillance. Fortunately, all surgical margins in this case were clear (i.e. no cancer was left behind).

There was a three-month interval between the initial diagnosis of T2 / grade group 1 disease and the post-prostatectomy analysis that revealed T3 / grade group 2 disease (90% Gleason 3, 10% Gleason 4). It is possible (although unlikely) that such deterioration may have resulted from rapid disease progression over this period rather than an underestimate by initial investigations. In any event, active surveillance would not have detected any such progression because the patient’s PSA levels remained stable and below 10 ng/mL up to the time of surgery, and repeat mpMRI and core biopsy would not have been conducted during the three-month interval as part of an active surveillance protocol.

The patient has had a very good clinical outcome and there has not been any BCR (see below). Nerve function has been preserved and he has no incontinence. His PSA is 0.01 ng/mL at five years after radical prostatectomy, reduced from 0.03 ng/mL at one year. Note that a PSA level of 0.01 ng/mL is the lower limit of quantification for the particular assay used in this case. PSA levels less than 0.01 ng/mL cannot be accurately quantified with this assay and would typically be reported as ‘undetectable’ or ‘less than 0.01 ng/mL’, but not as ‘zero’. Different PSA assays may have different lower limits of quantification, some below 0.01 ng/mL.

Postscript

The patient referred to in the clinical vignette wishes to express his gratitude to his general practitioner and urologist for their clinical acumen and surgical skill. He is equally grateful to a physician friend for her insistence that radical prostatectomy was the best treatment option.

Advantages/disadvantages of active surveillance

As demonstrated above, active surveillance is not without risk. The advantages/disadvantages of an active surveillance protocol can be summarised as follows:

  • strong trial evidence supporting safety
  • avoids unnecessary treatment
  • avoids potential adverse effects of treatments, maintains quality of life
  • mpMRI and biopsy may underestimate the severity of newly diagnosed disease
  • risks a missed opportunity for a cure
  • if cancer progresses during active surveillance, nerve preservation during subsequent prostatectomy may be more difficult
  • anxiety of living with untreated cancer
  • need for long-term, regular follow-up, including biopsies.

Radical prostatectomy and adverse events

Surgery for stages T1, T2 and T3 can be lifesaving. Radical prostatectomy involves the removal of the whole of the prostate gland while attempting to preserve urinary continence and sexual function. Some men may favour active surveillance owing to fear of surgery and its potential adverse events of incontinence and/or impotence.

The incidence of post-prostatectomy incontinence varies with the definition of the ailment and methods of evaluation.12 A patient who is ‘pad-free’ is generally used as a strict definition of continence, but the use of 0–1 pads per day is accepted as a definition of ‘social continence’.12,13

A substantial proportion of men suffer from incontinence following catheter removal after radical prostatectomy. Using 0–1 pads per day to define continence, 68% are continent by three months, almost 90% by one year and 93% by two years postoperatively.13–15

Robotic radical prostatectomy delivers greatly improved post-surgical continence compared with traditional open surgical methods; only a small minority require surgical intervention for ongoing problems.16

Post-surgery erectile dysfunction depends on a number of factors. Nonetheless, surgeons’ experience in techniques that spare vital nerves means there is a good chance of preserving sexual function.16,17 There are also options available to help, such as medications (tadalafil [Cialis], sildenafil [Viagra]) and penile implant. A urologist may prescribe daily tadalafil or sildenafil after surgery to help things along.

Finally, the term ‘total prostatectomy’ may be preferable to ‘radical prostatectomy’ when speaking to a man with prostate cancer. ‘Radical’ carries a slightly sinister undertone that may be off-putting. By comparison, the word ‘total’ carries an inherent reassurance that the entirety of the tumour will be removed.

Biochemical recurrence and the PSMA-PET scan

Although there are multiple definitions for BCR, many sources, including American clinical guidelines, define BCR after radical prostatectomy as a PSA level of ≥ 0.2 ng/mL on two consecutive occasions.18 Nevertheless, the clinical utility of this definition in the era of ultra-sensitive PSA assays remains an area of debate; some suggest that BCR post prostatectomy should be defined by PSA levels as low as 0.05 ng/mL under certain clinical circumstances, while others suggest that a PSA level of 0.4 ng/mL post radical prostatectomy is the best predictor of future metastatic disease.19,20 However, the story is more complex than deciding on a single PSA level to define BCR.

The natural history of BCR is highly variable, and not everyone who develops BCR will develop recurrent disease as evidenced by symptoms or evidence of recurrence on imaging.20 A single one-size-fits-all fixed PSA standard to define BCR may not be appropriate for all patients because detectable PSA levels have a different prognostic significance based on clinical and pathological risk factors and risk of cancer recurrence.19 For example, a PSA level of 0.05 ng/mL at one year after radical prostatectomy in a man with grade group 5 cancer with seminal vesicle invasion may be highly meaningful in terms of recurrence risk, but the same PSA level might not be meaningful in a man five years after radical prostatectomy with organ-confined, grade group 1 prostate cancer.19 Therefore, the indication for further therapy should not be based solely on meeting a threshold BCR PSA value, but should depend on an individual’s risk of recurrence.20 In high-risk prostate cancer, restaging (including imaging) and salvage therapy should not be delayed until a PSA reference standard has been reached.20

A persistent rise in PSA after prostatectomy generally prompts further investigation, usually with a prostate-specific membrane antigen positron emission tomography (PSMA-PET) scan, an imaging modality used to detect recurrent prostate cancer. The scan is generally accepted to be effective at detecting prostate cancer at a PSA level of 0.2 ng/mL or higher. As PSA increases, the scan becomes more effective because a rising PSA often means an increased volume of cancer. A PSMA-PET scan is frequently used in combination with a CT or MRI. Although a negative PSMA-PET scan result does not absolutely rule out recurrent prostate cancer, it is the best imaging modality that we currently possess and is substantially better than CT or MRI in detecting cancer recurrence.21–24

Recurrence risk calculator

A nomogram from the Memorial Sloan Kettering Cancer Center (see https://www.mskcc.org/nomograms/prostate) calculates:

  • the probability of remaining recurrence-free at 5, 10 and 15 years after prostatectomy
  • the probability of not dying from prostate cancer 15 years after prostatectomy.

The calculator uses the input of several pre- and post-operative parameters to calculate these probabilities.

Conclusion

Active surveillance is a valid tool for the management of early-stage / low-grade prostate cancer, but it is not without risk. Assessment by mpMRI/core biopsy may significantly underestimate the stage and grade of disease. In the clinical scenario presented, active surveillance for presumptive T2 / grade group 1 disease as assessed by mpMRI/core biopsy could have led to the patient delaying or even missing the window of opportunity for curative treatment, in what quickly proved to be T3 / grade group 2 disease.

This case also highlights the crucial importance of the treating general practitioner’s and urologist’s clinical judgement. Although the patient was a candidate for active surveillance on initial assessment, his urologist’s experience and clinical judgement led to a recommendation of radical prostatectomy, a decision validated by the subsequent analysis of the excised prostate gland.

This real-life experience may encourage others to be vigilant about the meaning of test results in relation to early management options, and to discuss surgery with their treating physician as an important, potentially curative treatment option. Surgery may be lifesaving and should not be avoided through fear of possible adverse effects.

Appendix 1. PI-RADS Score

Prostate Imaging Reporting and Data System (PI-RADS) is a 5-point scoring system used to assess the risk of clinically significant prostate cancer from mpMRI images. Scores of 4–5 suggest high risk, while 1–2 indicate low risk. Scoring varies slightly depending on whether the tumour is located in the peripheral zone or transition zone of the prostate gland. A score of 3 or higher indicates the need for a biopsy to be performed. PI-RADS is a screening tool; it does not provide a definitive diagnosis of prostate cancer—which is the task of core biopsy.

References

  1. Prostate Cancer Foundation of Australia. Active surveillance. 2026 [cited 2026 Aug 28]. Available from: https://www.prostate.org.au/treatments-side-effects/active-surveillance/
  2. Cancer Council Australia. Active surveillance for prostate cancer [cited 2026 Aug 28]. Available from: https://www.cancercouncil.com.au/prostate-cancer/management-treatment/active-surveillance/
  3. Newcomb LF, Schenk JM, Zheng Y, et al. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA 2024;331:2084-93. https://pubmed.ncbi.nlm.nih.gov/38814624/ DOI: 10.1001/jama.2024.6695
  4. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58. https://www.nejm.org/doi/full/10.1056/NEJMoa2214122 DOI: 10.1056/NEJMoa2214122
  5. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med 2017;377:132–42. https://www.nejm.org/doi/full/10.1056/NEJMoa1615869 DOI: 10.1056/NEJMoa1615869
  6. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13. https://www.nejm.org/doi/full/10.1056/NEJMoa1113162 DOI: 10.1056/NEJMoa1113162
  7. Epstein JI. Interpreting a pathology report: 15 biopsy and Gleason questions answered by a leading pathologist. Prostate Cancer Research Institute. 2016 Mar 10 [cited 2026 Aug 28]. Available from: https://pcri.org/news/2016/3/10/interpreting-a-pathology-report-15-biopsy-and-gleason-questions-answered-by-a-leading-pathologist
  8. Priester A, Natarajan S, Khoshnoodi P, et al. Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. J Urol 2017;197:320-6. https://pubmed.ncbi.nlm.nih.gov/27484386/ DOI: 10.1016/j.juro.2016.07.084
  9. W Ageeli. Preoperative Imaging in size determination of prostate cancer in men undergoing radical prostatectomy for clinically localised disease. Insights Imaging 2023;14:105. https://pubmed.ncbi.nlm.nih.gov/37286770/ DOI: 10.1186/s13244-023-01450-5
  10. Gaunay GS, Patel V, Shah P, et al. Multi-parametric MRI of the prostate: Factors predicting extracapsular extension at the time of radical prostatectomy. Asian J Urol 2017;4:31– 6. https://pubmed.ncbi.nlm.nih.gov/29264204/ DOI: 10.1016/j.ajur.2016.07.002
  11. Shaw GL, Thomas BC, Dawson SN, et al. Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. Br J Cancer 2014;110:2405-11. https://pubmed.ncbi.nlm.nih.gov/24722183/ DOI: 10.1038/bjc.2014.192
  12. Urinary incontinence after prostate treatment. UpToDate. 2024 [cited 2026 Aug 28]. Available from: https://www.uptodate.com/contents/urinary-incontinence-after-prostate-treatment?search=urinary%20incontinence%20following%20prostate%20treatment&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
  13. Sacco E, Prayer-Galetti T, Pinto F, et al. Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int 2006;97:1234–41. https://pubmed.ncbi.nlm.nih.gov/16686718/ DOI: 10.1111/j.1464-410X.2006.06185.x
  14. Donnellan SM, Duncan HJ, MacGregor RJ, Russell JM. Prospective assessment of incontinence after radical retropubic prostatectomy: objective and subjective analysis. Urology1997;49:225-30. https://www.sciencedirect.com/science/article/abs/pii/S0090429596004517/ DOI: 10.1016/S0090-4295(96)00451-7
  15. Hammerer P, Huland H. Urodynamic evaluation of changes in urinary control after radical retropubic prostatectomy. J Urol 1997;157:233-6. https://pubmed.ncbi.nlm.nih.gov/8976260/
  16. South Terrace Urology. Robotic surgery [cited 2026 Aug 28]. Available from: https://www.sturology.com.au/robotic-surgery/
  17. Ficarra V, Novara G, Ahlering TE, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012;62:418-30. https://pubmed.ncbi.nlm.nih.gov/22749850/ DOI: 10.1016/j.eururo.2012.05.046
  18. Lowrance W, Dreicer R, Jarrard DF, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol 2023;209:1082-90. https://pubmed.ncbi.nlm.nih.gov/37096583/ DOI: 10.1097/JU.0000000000003452
  19. Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol 2014;66:204-10. https://pubmed.ncbi.nlm.nih.gov/24007712/ DOI: 10.1016/j.eururo.2013.08.022
  20. Van den Broeck T, van den Bergh RCN, Briers E, et al. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus 2020;6:231-4. https://pubmed.ncbi.nlm.nih.gov/31248850/ DOI: 10.1016/j.euf.2019.06.004
  21. Barbosa FG, Queiroz MA, Nunes RF, Marin JFG, Buchpiguel CA, Cerri GG. Clinical perspectives of PSMA PET/MRI for prostate cancer. Clinics (Sao Paulo) 2018;73:e586s. https://pmc.ncbi.nlm.nih.gov/articles/PMC6142859/ DOI: 10.6061/clinics/2018/e586s
  22. Duan H, Iagaru A. PSMA PET for Detection of Recurrence. Semin Nucl Med 2024;54:77-86. https://pubmed.ncbi.nlm.nih.gov/37567795/ DOI: 10.1053/j.semnuclmed.2023.07.002
  23. Wang L, Wang L, Wang X, Wu D. The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact. Curr Oncol Rep 2025;27:774-87. https://pubmed.ncbi.nlm.nih.gov/40366535/ DOI: 10.1007/s11912-025-01682-2
  24. Bouchelouche K. Advances in PSMA Emission Tomography (PET) of Prostate Cancer. Current Opin Oncol 2018;30:189-96. https://pmc.ncbi.nlm.nih.gov/articles/PMC6003670/ DOI: 10.1097/CCO.0000000000000439

Acknowledgements: The authors wish to acknowledge the work of reviewer Dr Adrian Porter.

Funding statement: No funding was received for this work.

Conflict of interest statement: The authors declare no conflicts of interest.

Ethics approval: Not applicable.

Data availability statement: Not applicable.

Use of AI tools: Generative artificial intelligence tools were not used in the preparation of this manuscript, including for drafting text, data analysis, figure generation, or peer-reviewed responses.